Aspirin rarely used for colorectal cancer prevention
People with Lynch syndrome have a significantly increased risk of developing colorectal cancer and other types of cancer due to a hereditary predisposition. The CAPP2 study had already shown in this high-risk group that acetylsalicylic acid can significantly reduce the long-term risk of colorectal cancer. The study examined a comparatively high daily dose of 600 milligrams. The recently published…
A recent international study, CaPP3, published in The Lancet Gastroenterology & Hepatology, suggests that a daily dose of 100 milligrams of acetylsalicylic acid (commonly known as aspirin) could provide colorectal cancer prevention benefits for people with Lynch syndrome, a hereditary condition that significantly increases the risk of colorectal cancer.
This is in contrast to the CAPP2 study, which showed that a more substantial dose of 600 milligrams of aspirin was effective in reducing the long-term risk of the disease. The CaPP3 study, which involved 539 participants with Lynch syndrome across Germany, found that only 6.9% of the group currently used aspirin for cancer prevention, despite 97% being aware of the screening recommendations.
The main barriers to use were a lack of knowledge, concerns about side effects like bleeding, and uncertainty about the scientific evidence. Interestingly, the survey found that about three-quarters of respondents were open to participating in a preventive mRNA cancer vaccine study, indicating a strong willingness to engage with innovative preventive approaches.
The researchers emphasize the importance of providing clear, personalized information and support to help bridge the gap between scientific evidence, medical advice, and actual use of preventive measures like aspirin for Lynch syndrome.
Written by urgent.news from Medical Xpress's reporting — not their text. Machine-written — may contain errors; check the original before relying on it.
